Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Prado

Showing results (151-160 of 158) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 158 results.
Nature Communications|May 6, 2020
Author Correction: Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infectionEmily Adland, Jane Millar, Nomonde Bengu, et al.
Frontiers in Medicine|July 22, 2024
Long COVID: cognitive, balance, and retina manifestationsMeritxell Carmona-Cervelló, Brenda Biaani León-Gómez, Rosalia Dacosta-Aguayo, et al.
Iscience|November 2, 2022
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individualsErola Ainsua-Enrich, Núria Pedreño-Lopez, Carmen Bracke, et al.
The Journal of Infectious Diseases|October 6, 2022
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune ReconstitutionSusana Benet, Oscar Blanch-Lombarte, Erola Ainsua-Enrich, et al.
Journal of Virology|November 24, 2017
Differential Immunodominance Hierarchy of CD8<sup>+</sup> T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 InfectionEmily Adland, Matilda Hill, Nora Lavandier, et al.
Nature|February 27, 2009
Adaptation of HIV-1 to human leukocyte antigen class IYuka Kawashima, Katja Pfafferott, John Frater, et al.
Vaccine|January 14, 2025
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
The Lancet Regional Health. Europe|May 3, 2023
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Pageof 16

Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
Nature Communications|May 6, 2020
Author Correction: Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infectionEmily Adland, Jane Millar, Nomonde Bengu, et al.
Frontiers in Medicine|July 22, 2024
Long COVID: cognitive, balance, and retina manifestationsMeritxell Carmona-Cervelló, Brenda Biaani León-Gómez, Rosalia Dacosta-Aguayo, et al.
Iscience|November 2, 2022
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individualsErola Ainsua-Enrich, Núria Pedreño-Lopez, Carmen Bracke, et al.
The Journal of Infectious Diseases|October 6, 2022
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune ReconstitutionSusana Benet, Oscar Blanch-Lombarte, Erola Ainsua-Enrich, et al.
Journal of Virology|November 24, 2017
Differential Immunodominance Hierarchy of CD8<sup>+</sup> T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 InfectionEmily Adland, Matilda Hill, Nora Lavandier, et al.
Nature|February 27, 2009
Adaptation of HIV-1 to human leukocyte antigen class IYuka Kawashima, Katja Pfafferott, John Frater, et al.
Vaccine|January 14, 2025
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
The Lancet Regional Health. Europe|May 3, 2023
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Pageof 16